Dr Brown appointed to Advisory Board

By in ,

The information contained within this announcement is deemed by the Company to constitute inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014.  Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain. 

Sativa Investments PLC

 (“Sativa” or “the Company”)

Dr Matthew Brown, Pain Medicine & Anaesthetic Consultant appointed to Sativa’s Advisory Board

Sativa Investments PLC (NEX: SATI), the UK’s first medicinal cannabis investment vehicle,has appointed Dr Matthew Brown to its Medicinal Cannabis Advisory Board with immediate effect.

Dr Brown is an award-winning Consultant at The Royal Marsden Hospital specialising in pain medicine and anaesthetics and has recently published research into using cannabinoids for cancer pain treatment. Dr Brown holds an honorary research position at the Institute of Cancer Research having completed doctoral research into cancer-related pain at the institution, becoming the firstanaesthetist to complete a higher degree in the Institute’s history.

He has lectured on and produced research covering the breadth of cancer-related pain including chemotherapy induced neuropathy, persistent post-surgical pain as well as reducing pain associated with cancer usinghigh-intensity focused ultrasound (HIFU).  Dr Brown has won numerous awards throughout his career including the War Memorial Scholarship at King’s College London and the Chairman’s Prize on graduation from The Institute of Cancer Research.

Dr Brown’s training has come from a broad range of medical institutions across the UK.  He graduated from King’s College London with distinction in 2004.  His clinical training in pain medicine was gained at The Royal National Orthopaedic Hospital and the National Hospital for Neurology and Neurosurgery.  Dr Brown’s anaesthetic training was undertaken at the Imperial School of Anaesthesia in London, where he also received a placeon the prestigious National Institute for Health Research’s Academic Clinical Fellowship Programme.

Geremy Thomas, founder and Chief Executive Officer of Sativa Investments, said: “The new Home Office guidelines determining the prescription of Medicinal Cannabis encompass the treatment of pain and nausea in cancer patients.  Matthew’s qualifications and research in this area add even further to the input of Sativa’s top-level Medicinal Cannabis Advisory Board.  Patient outcome is the clear driver in the highly sensitive and prevalent area of cancer treatment.”

As at the date of this announcement, Dr Brown has unapproved share options in the Company over 76,923 shares at a strike price of 6.5p [NB this calculation is £5,000 / 6.5 pence.]

The Directors of the Company accept responsibility for the contents of this announcement.


For further information please contact:

Geremy Thomas

Founder & Chief Executive Officer

Sativa Investments PLC

+44 (0) 20 7971 1255


Joseph Colliver

Chief Financial Officer

Sativa Investments PLC

+44 (0) 20 7971 1255


NEX Exchange Corporate Adviser

Guy Miller and Lucy Williams

Peterhouse Capital Limited

+44 (0) 20 7469 0930





Financial PR and IR

Abchurch Communications

Julian Bosdet / Dylan Mark /

Alejandra Campuzano

Abchurch Switchboard


+44 (0) 20 7469 4633 / 4634

+44 (0) 20 7469 4630


Notes to Editors

Sativa invests in well-placed ventures within the dynamic regulatory environment of the Medicinal Cannabis sector. The Company’s pan-European, end-to-end, seed to consumer investment strategy focuses on the production, testing and compliance, research and development, including pharmacology, commercialisation and sales and marketing of Medicinal Cannabis in jurisdictions where it is regulatorily permitted.  Sativa has committed to an independent legal review prior to each investment to verify compliance with the prevailing regulatory environment.

The Company’s equity interest in an investment may range from a minority position, to a controlling interest, or to 100 per cent ownership.  The ventures that Sativa acquires can either be public or private.

Sativa Investments has four investments to date including Canadian-based and dual-listed emerging global pharmaceutical company,Veritas Pharma Inc., Toronto-based Pharma-Tech company Rapid Dose Therapeutics Inc., which owns the patent-pending proprietary QuickStrip™ technology, UK-based CBD products provider George Botanicals, and PhytoVista Laboratories, a UK testing laboratory meeting the need for regulatory and batch testing of products such as CBD oil.

The Company has a presence in Germany through its joint venture with Germany’s Lexamed GmbH; Sativa Germany GmbH, of which it has a 60 per cent majority stake in for the production of medicinal cannabis and CBD products.

The Company also has an option to lease a glasshouse facility in Wiltshire, with an up to 298,806 sq ft build out potential, togrow cannabis plants to produce medicinal cannabis and CBD products, which by law must contain a maximum 0.2 per cent THC.  The Company’s Chief Executive Officer, Geremy Thomas, has a UK hemp growers licence.

Sativa is also focussed on researching and developing medicinal cannabis products by funding university research grants of medicinal cannabis through its Sativa Foundation.

The Company’s Board and Medicinal Cannabis Advisory Board have a combined 60 years’ industry experience, with significant pharmaceutical strength and experience and extensive contacts in the industry, which includes pharmacologist Sir Alasdair Breckenridge, who liaises with the Home Office and the Medicines and Healthcare products Regulatory Agency, which he has chaired, for the legalisation of medicinal cannabis in the UK  Their extensive skills range from capital fund raisings, medical research, and start-ups, to pharmaceutical development.

For more information on Sativa Investments, please visit: www.sativagroup.co.uk

(1 vote. Average 5 of 5)
Leave a reply

Your email address will not be published. Required fields are marked *